Product Images Venlafaxine Hydrochloride

This is a description of Venlafaxine HCI medication produced by Zydus Pharm, Pennington, NJ 08534. It comes in a capsule form and has a quantity of 30. The package insert contains the directions for use, and it should be kept out of reach of children. The medication should be stored in a temperature range of 20-25°C (58-77°F) with permitted excursions to 15-30°C (59-86°F) and has been repackaged by RemedyRepack Inc, Indiana, PA 15701. The lot number, source NDC, and expiration date for the medication are available.*

This is a medication description for Venlafaxine HCI Extended-Release 37.5 mg capsules. It comes in a quantity of 90 and requires a prescription. The NDC number is 70518-0478-01 and the lot number, as well as the manufacturer, Zydus Pharm, is provided. The medication should be kept out of reach of children and stored at a temperature between 20-25°C (58-77°F), with excursions allowed up to 15-30°C (59-86°F). The provided directions for use are in the package insert. It has been repackaged by RemedyRepack Inc. in Indiana, PA.*

This is a list of interacting drugs with Ethanol, Diazepam, Cimetdine, and Ketoconazole in CYP2D6 EM's and PM's. It also includes recommended PK fold change and 90% C max, AUC, and clinical significance for certain drugs. It is unclear what the purpose of this list is for.*

This appears to be a table listing different drugs and their interactions with each other. The listed drugs include Diazepam, Alprazolam, Indinavir, Metoprolol, Risperidone, Imipramine, Haloperidol, Caffeine, and Lithium. The table also shows PKFold change and 90% CRecommendation for each analyte, as well as Cmax and Auc values.*

This is a report about the effects of specific populations and various impairments on the dosage requirements of the drug analyte venlafaxine. The populations studied include those with hepatic and renal impairments, CYP2D8 polymorphism, and advanced age or gender. For those with impairments or polymorphism, a reduction in dosage is recommended, while no adjustment is needed for the other populations. The report provides fold changes and 90% confidence intervals for the required dose changes.*